12 Month Price Forecast For FTRE
Distance to FTRE Price Forecasts
FTRE Price Momentum
๐ค Considering Fortrea Holdings (FTRE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 3:27 AM UTC
FTRE Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, FTRE has a consensus that is neutral. The median price target is $22.00, with forecasts ranging from $17.00 to $27.20. Currently, there are 1 Buy ratings, 10 Hold ratings, and 1 Sell ratings.
With FTRE currently trading at $15.56, the median price forecast suggests a 41.4% upside. The most optimistic forecast comes from at , projecting a 74.8% upside, while at provides the most conservative target, suggesting a 9.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FTRE Analyst Consensus
FTRE Price Target Range
Latest FTRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FTRE.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 11, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $23.00 |
Dec 6, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $25.00 |
Nov 25, 2024 | Baird | Outperform | Maintains | $0.00 | |
Nov 11, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $25.00 |
Nov 11, 2024 | TD Cowen | Charles Rhyee | Hold | Maintains | $25.00 |
Nov 11, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $30.00 |
Nov 8, 2024 | William Blair | Max Smock | Market Perform | Reiterates | $0.00 |
Oct 15, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $20.00 |
Oct 8, 2024 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $20.00 |
Oct 8, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $23.00 |
Sep 25, 2024 | Jefferies | David Windley | Hold | Downgrade | $21.00 |
Sep 11, 2024 | William Blair | Max Smock | Market Perform | Reiterates | $0.00 |
Aug 20, 2024 | Deutsche Bank | Justin Bowers | Hold | Maintains | $23.00 |
Aug 13, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $28.00 |
Aug 13, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $30.00 |
Aug 13, 2024 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $22.00 |
Aug 13, 2024 | B of A Securities | Derik De Bruin | Underperform | Maintains | $21.00 |
Aug 13, 2024 | TD Cowen | Charles Rhyee | Hold | Maintains | $23.00 |
Aug 13, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $21.00 |
Aug 12, 2024 | William Blair | Max Smock | Market Perform | Reiterates | $0.00 |
Stocks Similar to Fortrea Holdings Inc. - Common Stock
The following stocks are similar to Fortrea Holdings based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fortrea Holdings Inc. - Common Stock (FTRE) Financial Data
Fortrea Holdings Inc. - Common Stock has a market capitalization of $1.40B with a P/E ratio of 522.3x. The company generates $2.98B in trailing twelve-month revenue with a -10.1% profit margin.
Revenue growth is -5.5% quarter-over-quarter, while maintaining an operating margin of -1.4% and return on equity of -13.6%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Fortrea Holdings Inc. - Common Stock (FTRE) Company Overview
About Fortrea Holdings Inc. - Common Stock
Provides biopharmaceutical and medical device development services.
The company operates as a contract research organization (CRO), generating revenue by offering a range of clinical and enabling services to pharmaceutical, biotechnology, and medical device companies. Its business model includes various delivery structures, such as full service, functional service provider, and hybrid models, which cater to different client needs throughout the clinical trial process.
Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina. It specializes in managing clinical trials from phase I to IV and provides consulting services, leveraging technology to enhance trial efficiency and patient access.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15,500
CEO
Mr. Thomas H. Pike
Country
United States
IPO Year
2023
Website
www.fortrea.comFortrea Holdings Inc. - Common Stock (FTRE) Latest News & Analysis
Fortrea Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call
7 days agoFortrea (Nasdaq: FTRE) will release its Q4 and full-year 2024 financial results on March 3, 2025, before the market opens, followed by a conference call at 9:00 am ET.
Fortrea's upcoming financial results announcement and conference call may influence stock performance, investor sentiment, and expectations for future growth or challenges.
Pomerantz LLP is investigating claims for Fortrea Holdings Inc. (NASDAQ:FTRE) investors. Interested parties should contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980.
The investigation into Fortrea Holdings may indicate potential legal issues or financial irregularities, which could impact stock performance and investor sentiment.
Fortrea: Turning Around As The Activists Move In
1 month agoFortrea, a Labcorp spin-off, shows recovery potential with improved bookings, a 1.23x book-to-bill ratio, and a target price of $45 within a year, despite a 46% drop in 2024.
Fortrea's recovery signals potential for stock price appreciation due to improved bookings, activist interest, and favorable market conditions, with a target of $45 within a year.
Fortrea (Nasdaq: FTRE) will present at the Citi Global Healthcare Conference on December 4, 2024, at 1:45 pm ET, featuring CEO Tom Pike and CFO Jill McConnell.
CEO and CFO presentations at major conferences can influence investor sentiment, provide insights into company strategy, and affect stock performance, particularly in the healthcare sector.
Fortrea (Nasdaq: FTRE) will present at the Evercore HealthCONx Conference on December 5, 2024, at 10:00 am ET, featuring CEO Tom Pike and CFO Jill McConnell.
CEO and CFO presentations at a major conference can influence investor sentiment, potentially impacting stock price and market perception of Fortrea's growth and strategy.
Fortrea Holdings, Inc. will hold its Q3 2024 earnings conference call on November 8, 2024, at 8:00 AM ET, featuring key company executives and analysts from major financial institutions.
Fortrea's Q3 earnings call provides insights into financial performance, growth strategies, and market conditions, which can influence stock valuations and investment decisions.
Frequently Asked Questions About FTRE Stock
What is Fortrea Holdings Inc. - Common Stock's (FTRE) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Fortrea Holdings Inc. - Common Stock (FTRE) has a median price target of $22.00. The highest price target is $27.20 and the lowest is $17.00.
Is FTRE stock a good investment in 2025?
According to current analyst ratings, FTRE has 1 Buy ratings, 10 Hold ratings, and 1 Sell ratings. The stock is currently trading at $15.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for FTRE stock?
Wall Street analysts predict FTRE stock could reach $22.00 in the next 12 months. This represents a 41.4% increase from the current price of $15.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fortrea Holdings Inc. - Common Stock's business model?
The company operates as a contract research organization (CRO), generating revenue by offering a range of clinical and enabling services to pharmaceutical, biotechnology, and medical device companies. Its business model includes various delivery structures, such as full service, functional service provider, and hybrid models, which cater to different client needs throughout the clinical trial process.
What is the highest forecasted price for FTRE Fortrea Holdings Inc. - Common Stock?
The highest price target for FTRE is $27.20 from at , which represents a 74.8% increase from the current price of $15.56.
What is the lowest forecasted price for FTRE Fortrea Holdings Inc. - Common Stock?
The lowest price target for FTRE is $17.00 from at , which represents a 9.3% increase from the current price of $15.56.
What is the overall FTRE consensus from analysts for Fortrea Holdings Inc. - Common Stock?
The overall analyst consensus for FTRE is neutral. Out of 12 Wall Street analysts, 1 rate it as Buy, 10 as Hold, and 1 as Sell, with a median price target of $22.00.
How accurate are FTRE stock price projections?
Stock price projections, including those for Fortrea Holdings Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.